Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immunitybio Inc IBRX

Healthcare Biotechnology
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the... see more

Current News (NDAQ:IBRX)

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Business Wire 2 days ago

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Business Wire 10 days ago

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Business Wire September 8, 2025

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

Business Wire August 19, 2025

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

Business Wire August 13, 2025

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Business Wire August 5, 2025

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

Business Wire July 25, 2025

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

Business Wire July 25, 2025

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Business Wire July 7, 2025
View More News ››

Opinion & Analysis (NDAQ:IBRX)

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Streetwise Reports January 17, 2020

CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

Gail Dutton September 10, 2015
View More Opinion ››

Bullboard Posts (NDAQ:IBRX)

Still staying with this stock

It should be going up today and tomorrow
coolfooldumbguy - February 28, 2025

Buy buddy buy because it's taking off this morning.

This stock is signalling a big uptrend today so that you guys should be getting on-board
coolfooldumbguy - February 19, 2025

South Africa to make Immunities Vac.

ImmunityBio's COVID-19 Vaccine Will Be Manufactured In South Africa: Bloomberg (yahoo.com)
tturner617 - March 19, 2021

Feb 5 21.. Pill Now being tested

In S. Africa....  Covid vaccine pill enters clinical trials - Research Professional News
tturner617 - February 7, 2021

doubled investment in 3 weeks

Id say NK has considerable upside yet. They are on the warp 14 list for covid 19 vaccine development, their serum base has already been...
Covey1000 - June 3, 2020

*Crickets*

Is it over already? Has it just begun? What say you....
happerdan - May 27, 2020
View more Bullboard ››

Spirit Blockchain Capital Inc.

Spirit Blockchain Capital Inc.

Spirit Blockchain Capital Inc. is an investment company focused on the blockchain industry. Through its operational business ...
View More »